227 related articles for article (PubMed ID: 31901178)
1. Phenotypical and potential functional characteristics of different immune cells expressing CD28H/B7-H5 and their relationship with cancer prognosis.
Zhong C; Lang Q; Yu J; Wu S; Xu F; Tian Y
Clin Exp Immunol; 2020 Apr; 200(1):12-21. PubMed ID: 31901178
[TBL] [Abstract][Full Text] [Related]
2. B7-H5/CD28H is a co-stimulatory pathway and correlates with improved prognosis in pancreatic ductal adenocarcinoma.
Chen Q; Wang J; Chen W; Zhang Q; Wei T; Zhou Y; Xu X; Bai X; Liang T
Cancer Sci; 2019 Feb; 110(2):530-539. PubMed ID: 30548441
[TBL] [Abstract][Full Text] [Related]
3. CD28 Homolog Is a Strong Activator of Natural Killer Cells for Lysis of B7H7
Zhuang X; Long EO
Cancer Immunol Res; 2019 Jun; 7(6):939-951. PubMed ID: 31018957
[TBL] [Abstract][Full Text] [Related]
4. CD28H expression identifies resident memory CD8 + T cells with less cytotoxicity in human peripheral tissues and cancers.
Tian Y; Sun Y; Gao F; Koenig MR; Sunderland A; Fujiwara Y; Torphy RJ; Chen L; Edil BH; Schulick RD; Zhu Y
Oncoimmunology; 2019; 8(2):e1538440. PubMed ID: 30713797
[TBL] [Abstract][Full Text] [Related]
5. B7-H5 costimulates human T cells via CD28H.
Zhu Y; Yao S; Iliopoulou BP; Han X; Augustine MM; Xu H; Phennicie RT; Flies SJ; Broadwater M; Ruff W; Taube JM; Zheng L; Luo L; Zhu G; Chen J; Chen L
Nat Commun; 2013; 4():2043. PubMed ID: 23784006
[TBL] [Abstract][Full Text] [Related]
6. The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.
Janakiram M; Shah UA; Liu W; Zhao A; Schoenberg MP; Zang X
Immunol Rev; 2017 Mar; 276(1):26-39. PubMed ID: 28258693
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of B7H5/CD28H is associated with worse survival in human gastric cancer.
Hu C; Xu Z; Chen S; Lv H; Wang Y; Wang X; Mo S; Shi C; Wei S; Hu L; Chen W; Cheng X
J Cell Mol Med; 2020 Jan; 24(2):1360-1369. PubMed ID: 31883303
[TBL] [Abstract][Full Text] [Related]
8. New B7 Family Checkpoints in Human Cancers.
Ni L; Dong C
Mol Cancer Ther; 2017 Jul; 16(7):1203-1211. PubMed ID: 28679835
[TBL] [Abstract][Full Text] [Related]
9. Phenotype and tissue distribution of CD28H
Crespo J; Vatan L; Maj T; Liu R; Kryczek I; Zou W
Oncoimmunology; 2017; 6(12):e1362529. PubMed ID: 29209568
[TBL] [Abstract][Full Text] [Related]
10. B7-H7 Is Inducible on T Cells to Regulate Their Immune Response and Serves as a Marker for Exhaustion.
Luu K; Schwarz H; Lundqvist A
Front Immunol; 2021; 12():682627. PubMed ID: 34140952
[TBL] [Abstract][Full Text] [Related]
11. A B7-CD28 family based signature demonstrates significantly different prognoses and tumor immune landscapes in lung adenocarcinoma.
Zheng S; Luo X; Dong C; Zheng D; Xie J; Zhuge L; Sun Y; Chen H
Int J Cancer; 2018 Nov; 143(10):2592-2601. PubMed ID: 30152019
[TBL] [Abstract][Full Text] [Related]
12. Soluble B7-CD28 Family Inhibitory Immune Checkpoint Proteins and Anti-Cancer Immunotherapy.
Khan M; Arooj S; Wang H
Front Immunol; 2021; 12():651634. PubMed ID: 34531847
[TBL] [Abstract][Full Text] [Related]
13. The B7 Family Member B7-H6: a New Bane of Tumor.
Chen Y; Mo J; Jia X; He Y
Pathol Oncol Res; 2018 Oct; 24(4):717-721. PubMed ID: 29086181
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of B7 co-stimulatory molecules by astrocytes correlates with T cell activation and cytokine production.
Soos JM; Ashley TA; Morrow J; Patarroyo JC; Szente BE; Zamvil SS
Int Immunol; 1999 Jul; 11(7):1169-79. PubMed ID: 10383950
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells.
Fiegler N; Textor S; Arnold A; Rölle A; Oehme I; Breuhahn K; Moldenhauer G; Witzens-Harig M; Cerwenka A
Blood; 2013 Aug; 122(5):684-93. PubMed ID: 23801635
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function.
Lee YH; Martin-Orozco N; Zheng P; Li J; Zhang P; Tan H; Park HJ; Jeong M; Chang SH; Kim BS; Xiong W; Zang W; Guo L; Liu Y; Dong ZJ; Overwijk WW; Hwu P; Yi Q; Kwak L; Yang Z; Mak TW; Li W; Radvanyi LG; Ni L; Liu D; Dong C
Cell Res; 2017 Aug; 27(8):1034-1045. PubMed ID: 28685773
[TBL] [Abstract][Full Text] [Related]
17. Targeting the B7 family of co-stimulatory molecules: successes and challenges.
Podojil JR; Miller SD
BioDrugs; 2013 Feb; 27(1):1-13. PubMed ID: 23329394
[TBL] [Abstract][Full Text] [Related]
18. Expression of the Novel Costimulatory Molecule B7-H5 in Pancreatic Cancer.
Byers JT; Paniccia A; Kaplan J; Koenig M; Kahn N; Wilson L; Chen L; Schulick RD; Edil BH; Zhu Y
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1574-9. PubMed ID: 25519928
[TBL] [Abstract][Full Text] [Related]
19. CD28/B7 Deficiency Attenuates Systolic Overload-Induced Congestive Heart Failure, Myocardial and Pulmonary Inflammation, and Activated T Cell Accumulation in the Heart and Lungs.
Wang H; Kwak D; Fassett J; Hou L; Xu X; Burbach BJ; Thenappan T; Xu Y; Ge JB; Shimizu Y; Bache RJ; Chen Y
Hypertension; 2016 Sep; 68(3):688-96. PubMed ID: 27432861
[TBL] [Abstract][Full Text] [Related]
20. CD28/B7 costimulation: a review.
Greenfield EA; Nguyen KA; Kuchroo VK
Crit Rev Immunol; 1998; 18(5):389-418. PubMed ID: 9784967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
